Hanmi Pharm Co Ltd (128940) - Net Assets

Latest as of September 2025: ₩1.35 Trillion KRW ≈ $911.96 Million USD

Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) has net assets worth ₩1.35 Trillion KRW (≈ $911.96 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.04 Trillion ≈ $1.38 Billion USD) and total liabilities (₩694.79 Billion ≈ $470.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hanmi Pharm Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩1.35 Trillion
% of Total Assets	65.95%
Annual Growth Rate	10.03%
5-Year Change	49.15%
10-Year Change	66.59%
Growth Volatility	8.39

Hanmi Pharm Co Ltd - Net Assets Trend (2010–2024)

This chart illustrates how Hanmi Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 128940 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Hanmi Pharm Co Ltd (2010–2024)

The table below shows the annual net assets of Hanmi Pharm Co Ltd from 2010 to 2024. For live valuation and market cap data, see Hanmi Pharm Co Ltd (128940) market capitalisation.

Year	Net Assets	Change
2024-12-31	₩1.24 Trillion ≈ $840.84 Million	+12.77%
2023-12-31	₩1.10 Trillion ≈ $745.60 Million	+9.02%
2022-12-31	₩1.01 Trillion ≈ $683.94 Million	+8.72%
2021-12-31	₩928.26 Billion ≈ $629.07 Million	+11.58%
2020-12-31	₩831.89 Billion ≈ $563.76 Million	+1.17%
2019-12-31	₩822.26 Billion ≈ $557.23 Million	+4.18%
2018-12-31	₩789.26 Billion ≈ $534.87 Million	-0.40%
2017-12-31	₩792.42 Billion ≈ $537.01 Million	+7.88%
2016-12-31	₩734.52 Billion ≈ $497.77 Million	-1.38%
2015-12-31	₩744.81 Billion ≈ $504.75 Million	+26.40%
2014-12-31	₩589.25 Billion ≈ $399.32 Million	+27.29%
2013-12-31	₩462.92 Billion ≈ $313.71 Million	+13.09%
2012-12-31	₩409.34 Billion ≈ $277.41 Million	+8.23%
2011-12-31	₩378.22 Billion ≈ $256.32 Million	+16.24%
2010-12-31	₩325.38 Billion ≈ $220.50 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Hanmi Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 68088799061000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	₩680.89 Billion	62.76%
Other Components	₩404.01 Billion	37.24%
Total Equity	₩1.08 Trillion	100.00%

Hanmi Pharm Co Ltd Competitors by Market Cap

The table below lists competitors of Hanmi Pharm Co Ltd ranked by their market capitalization.

Company	Market Cap
Cosan SA ADR NYSE:CSAN	$3.96 Billion
Iljin Electric Co KO:103590	$3.96 Billion
Harvey Norman Holdings Ltd AU:HVN	$3.96 Billion
Blue Star Limited NSE:BLUESTARCO	$3.96 Billion
Shake Shack Inc NYSE:SHAK	$3.95 Billion
Caesars Entertainment Corporation NASDAQ:CZR	$3.95 Billion
H&R Block Inc NYSE:HRB	$3.95 Billion
Asbury Automotive Group Inc NYSE:ABG	$3.95 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hanmi Pharm Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 955,442,389,530 to 1,084,893,341,850, a change of 129,450,952,320 (13.5%).
Net income of 121,315,102,380 contributed positively to equity growth.
Dividend payments of 12,555,417,680 reduced retained earnings.
Share repurchases of 3,280,080,960 reduced equity.
Other factors increased equity by 23,971,348,580.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩121.32 Billion	+11.18%
Dividends Paid	₩12.56 Billion	-1.16%
Share Repurchases	₩3.28 Billion	-0.3%
Other Changes	₩23.97 Billion	+2.21%
Total Change	₩-	13.55%

Book Value vs Market Value Analysis

This analysis compares Hanmi Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.38x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 7.62x to 5.38x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩60354.92	₩460000.00	x
2018-12-31	₩59685.60	₩460000.00	x
2019-12-31	₩61478.56	₩460000.00	x
2020-12-31	₩62059.72	₩460000.00	x
2021-12-31	₩65610.38	₩460000.00	x
2022-12-31	₩70009.40	₩460000.00	x
2023-12-31	₩75287.84	₩460000.00	x
2024-12-31	₩85557.97	₩460000.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hanmi Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 11.18%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 8.11%
• Asset Turnover: 0.74x
• Equity Multiplier: 1.86x
Recent ROE (11.18%) is above the historical average (8.27%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	0.38%	0.21%	0.77x	2.34x	₩-32.34 Billion
2012	6.25%	3.36%	0.81x	2.31x	₩-13.61 Billion
2013	10.73%	6.02%	0.83x	2.15x	₩2.99 Billion
2014	6.73%	4.66%	0.74x	1.96x	₩-17.24 Billion
2015	22.88%	11.72%	0.76x	2.55x	₩86.95 Billion
2016	3.54%	2.64%	0.55x	2.42x	₩-42.62 Billion
2017	8.49%	6.59%	0.55x	2.33x	₩-10.74 Billion
2018	3.54%	2.45%	0.60x	2.40x	₩-45.43 Billion
2019	7.20%	4.68%	0.58x	2.64x	₩-20.27 Billion
2020	1.64%	1.11%	0.57x	2.58x	₩-61.04 Billion
2021	8.35%	5.57%	0.62x	2.41x	₩-13.27 Billion
2022	9.50%	6.22%	0.69x	2.21x	₩-4.39 Billion
2023	15.31%	9.81%	0.79x	1.99x	₩50.69 Billion
2024	11.18%	8.11%	0.74x	1.86x	₩12.83 Billion

Industry Comparison

This section compares Hanmi Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $417,135,058,503
Average return on equity (ROE) among peers: 2.50%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hanmi Pharm Co Ltd (128940)	₩1.35 Trillion	0.38%	0.52x	$3.95 Billion
Dongwha Pharm.Co.Ltd (000020)	$296.94 Billion	15.83%	0.24x	$113.83 Million
Yuhan Corp. (000100)	$756.45 Billion	11.87%	0.32x	$4.57 Billion
Yuhan Corp Preferred (000105)	$1.61 Trillion	6.79%	0.30x	$59.61 Million
Yuyu Pharma (000220)	$73.73 Billion	-0.34%	0.41x	$46.55 Million
Yuyu Pharma Inc (000225)	$123.37 Billion	-4.85%	0.58x	$17.67 Million
Yuyu Pharma Inc (000227)	$71.49 Billion	-10.45%	0.42x	$42.93 Million
Ildong Holdings Co Ltd (000230)	$164.95 Billion	-2.25%	0.61x	$76.14 Million
Samil Pharm (000520)	$65.75 Billion	-8.13%	2.44x	$127.90 Million
Donga Socio Holdings (000640)	$746.90 Billion	2.65%	0.82x	$427.15 Million
Jw Pharmac (001060)	$265.44 Billion	13.94%	1.43x	$476.78 Million

About Hanmi Pharm Co Ltd

KO:128940 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$3.95 Billion

₩5.83 Trillion KRW

Market Cap Rank

#4184 Global

#110 in Korea

Share Price

₩460000.00

Change (1 day)

-4.76%

52-Week Range

₩257500.00 - ₩626000.00

All Time High

₩666173.23